3.5.4.4 (+)-erythro-9-(2-hydroxy-3-nonyl)adenine specific inhibitor of ADA1 163510 3.5.4.4 (+)-erythro-9-(2-hydroxy-3-nonyl)adenine - 163510 3.5.4.4 (2S,3R)-3-(6-amino-9H-purin-9-yl)-5-[3-(trifluoromethyl)phenyl]pentan-2-ol comopound shows suitable balance of potency, microsomal stability and demonstrates better pharmacokinetic properties as compared to (+)-erythro-9-(2-hydroxy-3-nonyl)adenine 237480 3.5.4.4 (2S,3R)-3-(6-amino-9H-purin-9-yl)-5-[4-(trifluoromethyl)phenyl]pentan-2-ol comopound shows suitable balance of potency, microsomal stability and demonstrates better pharmacokinetic properties as compared to (+)-erythro-9-(2-hydroxy-3-nonyl)adenine 237481 3.5.4.4 (2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol - 42126 3.5.4.4 (S)-(-)-epoxydecane - 132683 3.5.4.4 1,6-Dihydro-6-(hydroxymethyl)purine riboside - 90438 3.5.4.4 1-(4-benzylphenyl)-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea - 74003 3.5.4.4 1-(4-fluorophenyl)-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea - 74000 3.5.4.4 1-(4-methoxyphenyl)-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea - 73999 3.5.4.4 1-(hydroxymethyl)nonyl methanesulfonate - 132682 3.5.4.4 1-(tert-butyldimethylsilanyloxy)-decan-2-ol - 132680 3.5.4.4 1-(tert-butyldimethylsilanyloxymethyl)nonyl methanesulfonate - 132681 3.5.4.4 1-alkyl-3-amino-4-pyrazolecarbonitriles - 132674 3.5.4.4 1-alkyl-4-aminopyrazolo[3,4d]pyrimidines - 132684 3.5.4.4 1-benzyl-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea - 74005 3.5.4.4 1-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine i.e. 1-dEHNA 11669 3.5.4.4 1-deazaadenosine - 6846 3.5.4.4 1-methyl adenosine - 103801 3.5.4.4 1-[(1R)-1-(hydroxymethyl)-3-(6-[[(1-methyl-1H-benzimidazol-2-yl)acetyl]amino]-1H-indol-1-yl)propyl]-1H-imidazole-4-carboxamide - 73992 3.5.4.4 1-[(1R)-1-(hydroxymethyl)-3-naphthalen-1-ylpropyl]-1H-imidazole-4-carboxamide - 73988 3.5.4.4 1-[(1R)-1-(hydroxymethyl)-3-phenylpropyl]-1H-imidazole-4-carboxamide - 73987 3.5.4.4 1-[(1R)-2-hydroxy-1-phenylethyl]-1H-imidazole-4-carboxamide - 73986 3.5.4.4 1-[(1R)-3-[6-(acetylamino)-1H-indol-1-yl]-1-(hydroxymethyl)propyl]-1H-imidazole-4-carboxamide - 73990 3.5.4.4 1-[(1R)-3-[6-(hexanoylamino)-1H-indol-1-yl]-1-(hydroxymethyl)propyl]-1H-imidazole-4-carboxamide - 73991 3.5.4.4 1-[(1R,2S)-2-hydroxy-1-(2-naphthalen-1-ylethyl)propyl]-1H-imidazole-4-carboxamide - 73989 3.5.4.4 1-[(2S,3R)-2,3-dihydroxycyclopentyl]-5-(1,3-thiazol-5-yl)pyrimidine-2,4(1H,3H)-dione 28% inhibition at 0.1 mM 204831 3.5.4.4 1-[(2S,3R)-2,3-dihydroxycyclopentyl]-5-(furan-2-yl)pyrimidine-2,4(1H,3H)-dione 35% inhibition at 0.1 mM 204832 3.5.4.4 1-[(2S,3R)-2,3-dihydroxycyclopentyl]-5-(thiophen-2-yl)pyrimidine-2,4(1H,3H)-dione 36% inhibition at 0.1 mM 204833 3.5.4.4 1-[(3R,4S)-4-hydroxy-1-[3-(trifluoromethyl)phenyl]pentan-3-yl]-1H-imidazole-4-carboxamide comopound shows suitable balance of potency, microsomal stability and demonstrates better pharmacokinetic properties as compared to (+)-erythro-9-(2-hydroxy-3-nonyl)adenine 237482 3.5.4.4 1-[(4R,5S)-4,5-dihydroxycyclopent-2-en-1-yl]-5-(1,3-thiazol-5-yl)pyrimidine-2,4(1H,3H)-dione 49% inhibition at 0.1 mM 204845 3.5.4.4 1-[(4R,5S)-4,5-dihydroxycyclopent-2-en-1-yl]-5-(furan-2-yl)pyrimidine-2,4(1H,3H)-dione 55% inhibition at 0.1 mM 204846 3.5.4.4 1-[(4R,5S)-4,5-dihydroxycyclopent-2-en-1-yl]-5-(thiophen-2-yl)pyrimidine-2,4(1H,3H)-dione 48% inhibition at 0.1 mM 204847 3.5.4.4 1-[(R)-1-hydroxy-4-(1-methyl-5-(3-phenylpropoxy)indol-3-yl)-2-butyl]imidazole-4-carboxamide - 60990 3.5.4.4 1-[(R)-1-hydroxy-4-(5-(3-phenylpropoxy)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60987 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(3-(1-methylbenzimidazol-2-yl)propionylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60971 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(3-(3-pyridyl)propionylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60980 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(3-(4-methoxyphenyl)propionylamino)indol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60978 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(3-(4-methylphenyl)propionylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60977 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(3-phenylpropionylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60972 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(3-phenylpropoxy)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60982 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(4-(4-methylphenyl)butyrylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60979 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(4-phenylbutoxy)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60983 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(4-phenylbutyrylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60975 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(5-phenylvalerylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60970 3.5.4.4 1-[(R)-1-hydroxy-4-(6-(6-phenylhexanoylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide - 60976 3.5.4.4 1-[(R)-4-(5-(3-(4-chlorophenyl)propoxyl)-1-methylindol-3-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60989 3.5.4.4 1-[(R)-4-(5-hexyloxy-1-methylindol-3-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60991 3.5.4.4 1-[(R)-4-(5-hexyloxyindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60988 3.5.4.4 1-[(R)-4-(6-(3-(4-chlorophenyl)propoxy)indol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60986 3.5.4.4 1-[(R)-4-(6-(3-benzylureido)indol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60981 3.5.4.4 1-[(R)-4-(6-acetylaminoindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60973 3.5.4.4 1-[(R)-4-(6-butoxyindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60985 3.5.4.4 1-[(R)-4-(6-hexanoylaminoindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60974 3.5.4.4 1-[(R)-4-(6-hexyloxyindol-1-yl)-1-hydroxy-2-butyl]imidazole-4-carboxamide - 60984 3.5.4.4 1-[4-(dimethylamino)phenyl]-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea - 74002 3.5.4.4 1-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-3-(4-phenoxyphenyl)urea - 74004 3.5.4.4 1-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-3-phenylurea - 73998 3.5.4.4 1-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-3-[4-(trifluoromethyl)phenyl]urea - 74001 3.5.4.4 2',3'-o-isopropyliden adenosine - 104380 3.5.4.4 2'-deoxy-4-amino-1-(beta-D-ribofuranosyl)-3H-imidazo[4,5-d]pyridazin-7-(6H)-one - 69263 3.5.4.4 2'-deoxy-7-amino-1-(beta-D-ribofuranosyl)-1H-imidazo[4,5-d]pyridazin-4-(5H)-one - 69264 3.5.4.4 2'-deoxycoformycin 0.0015 nM, 50% inhibition 5090 3.5.4.4 2'-deoxycoformycin 0.0004 nM, 50% inhibition 5090 3.5.4.4 2'-deoxycoformycin 0.15 nM, 50% inhibition 5090 3.5.4.4 2'-deoxycoformycin a natural product transition state analogue inhibitor 5090 3.5.4.4 2'-deoxycoformycin - 5090 3.5.4.4 2'-deoxyformycin 50% inhibition of isozyme ADA2 at 0.09 mM 132687 3.5.4.4 2'-deoxyinosine - 2187 3.5.4.4 2,2,2-trifluoro-N-[7-chloro-5-methyl-3-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridin-6-yl]-acetamide 20% inhibition at 0.4 mM 206629 3.5.4.4 2,2,2-trifluoro-N-[7-chloro-5-methyl-3-(beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridin-6-yl]acetamide 23% inhibition at 0.4 mM 206630 3.5.4.4 2,6-diaminopurine - 2634 3.5.4.4 2,6-diaminopurine sulfate - 103807 3.5.4.4 2-alkyl-4-aminopyrazolo[3,4d]pyrimidines - 132678 3.5.4.4 2-Amino-4-hydroxypteridine - 5093 3.5.4.4 2-Aminopurine - 6419 3.5.4.4 2-Aminopurine competitive inhibition 6419 3.5.4.4 2-Deoxycoformycin - 43123 3.5.4.4 2-mercaptoethanol - 63 3.5.4.4 3-amino-1-(2-hydroxy-3-nonyl)4-pyrazolecarbonitrile - 132677 3.5.4.4 3-amino-1-(2-keto-3-nonyl)4-pyrazolecarbonitrile - 132676 3.5.4.4 3-amino-1-beta-hydroxyalkyl-4-pyrazolecarbonitriles - 132675 3.5.4.4 3-deaza-erythro-9-(2-hydroxy-3-nonyl)adenine i.e. 3-dEHNA 11670 3.5.4.4 3-deazaadenosine - 2189 3.5.4.4 4-acetylamino-2-decylpyrazolo[3,4d]pyrimidine - 132679 3.5.4.4 4-amino-1-(2-hydroxy-3-nonyl)pyrazolo[3,4d]pyrimidine - 60968 3.5.4.4 4-amino-1-(beta-D-ribofuranosyl)-3H-imidazo[4,5-d]pyridazin-7-(6H)-one - 69265 3.5.4.4 4-amino-1-(beta-hydroxyethyl)pyrazolo[3,4d]pyrimidine - 60969 3.5.4.4 4-amino-1-(beta-hydroxyoctyl)pyrazolo[3,4d]pyrimidine - 132685 3.5.4.4 4-amino-2-(2-hydroxy-1-decyl)pyrazole[3,4-d]pyrimidine i.e. APP 144059 3.5.4.4 4-amino-2-decyl-6-phenylpyrazolo[3,4d]pyrimidine - 132686 3.5.4.4 4-amino-5-imidazole carboxamide-HCl - 103829 3.5.4.4 4-amino-5-imidazole carboxyamide ribonucleoside - 104960 3.5.4.4 4-aminopyridine competitive inhibition 13387 3.5.4.4 4-aminopyrimidine competitive inhibition 69271 3.5.4.4 4-fluoro-N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]benzamide - 73995 3.5.4.4 4-hydroxypyridine competitive inhibition 10837 3.5.4.4 4-methoxy-N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]benzamide - 73994 3.5.4.4 5'-methylthio-2'-deoxycoformycin - 69269 3.5.4.4 5'-methylthiocoformycin - 5418 3.5.4.4 5'-methylthiocoformycin specific transition state analogue inhibitor of Plasmodium ADA 5418 3.5.4.4 5'-methylthiocoformycin specific transition state analogue inhibitor of Plasmodium ADA, 5'-methylthiocoformycin is a subnanomolar inhibitor of Plasmodium falciparum ADA and demonstrates more than 20000fold selectivity relative to human ADA 5418 3.5.4.4 5'-methylthiocoformycin poor inhibitor of Plasmodium gallinaceum ADA 5418 3.5.4.4 5-(beta-D-ribofuranosyl)-1H,5H-imidazo[4,5-b]pyrazolo[3,4-e]pyridine 25% inhibition at 0.4 mM 206627 3.5.4.4 5-carbamimidoyl-1-(beta-D-ribofuranosyl)-1H-imidazole-4-carbohydrazide - 69267 3.5.4.4 5-methyl-3-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridin-6-amine 19% inhibition at 0.4 mM 206625 3.5.4.4 5-methyl-3-(beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridin-6-amine 6% inhibition at 0.4 mM 206626 3.5.4.4 5-methyl-6-nitro-3-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridine 31% inhibition at 0.4 mM 206623 3.5.4.4 5-methyl-6-nitro-3-(beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridine 25% inhibition at 0.4 mM 206624 3.5.4.4 6-Chloropurine - 2823 3.5.4.4 6-fluoro-D,L-tryptophan adenosine analogue, induces conformational changes inhibiting the enzyme, structural mechanism, overview 132672 3.5.4.4 6-methylamino riboside - 48758 3.5.4.4 6-Methylmercaptopurine riboside - 5922 3.5.4.4 7,8-dihydro-1-p-methoxybenzyl-6H-6,7-dimethyl-8-propoxyimidazo[4,5-e][1,2,4]-triazepine - 56223 3.5.4.4 7,8-dihydro-1-p-methoxybenzyl-8-(2-methoxyethoxy)-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine - 56226 3.5.4.4 7,8-dihydro-1-p-methoxybenzyl-8-(3-methylbenzyloxy)-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine - 56228 3.5.4.4 7,8-dihydro-1-p-methoxybenzyl-8-(4-methoxybenzyloxy)-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine - 56227 3.5.4.4 7,8-dihydro-8-ethoxy-1-p-methoxybenzyl-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine - 56222 3.5.4.4 7,8-dihydro-8-isopropoxy-1-p-methoxybenzyl-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine - 56225 3.5.4.4 7,8-dihydro-8-methoxy-1-p-methoxybenzyl-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine - 56221 3.5.4.4 7-(beta-D-ribofuranosyl)-1H,7H-imidazo[4,5-b]pyrazolo[3,4-e]pyridine 7% inhibition at 0.4 mM 206628 3.5.4.4 7-amino-1-(beta-D-ribofuranosyl)-1H-imidazo[4,5-d]pyridazin-4-(5H)-one - 69266 3.5.4.4 7-chloro-5-methyl-3-(beta-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridin-6-amine 15% inhibition at 0.4 mM 206631 3.5.4.4 8-Bromoadenosine - 9087 3.5.4.4 8-butoxy-7,8-dihydro-1-p-methoxybenzyl-6H-6,7-dimethylimidazo[4,5-e][1,2,4]triazepine - 56224 3.5.4.4 9-(p-aminobenzyl)adenine - 105317 3.5.4.4 acetaminophen competitive at 27°C, uncompetitive at 37°C 2541 3.5.4.4 Acetylsalicylic acid - 2261 3.5.4.4 adenine - 144 3.5.4.4 adenine competitive inhibition 144 3.5.4.4 adenosine analogs - 105369 3.5.4.4 adenosine analogues induce conformational changes inhibiting the enzyme, structural mechanism, overview 132673 3.5.4.4 adenosine monosulfate - 92294 3.5.4.4 Ag+ - 75 3.5.4.4 Ag2+ - 1041 3.5.4.4 aminoxyacetic acid - 92440 3.5.4.4 AMP - 30 3.5.4.4 aspirin significantly decreases adenosine deaminase activity, the half-life of adenosine will be lengthened as a consequence of decreased adenosine deaminase activity 3100 3.5.4.4 ATP - 4 3.5.4.4 aza adenosine analogues - 105497 3.5.4.4 Ba2+ 44% inhibition at 5 mM 111 3.5.4.4 basic histone proteins - 105510 3.5.4.4 Ca2+ 69% inhibition at 5 mM 15 3.5.4.4 Ca2+ strong inhibition 15 3.5.4.4 caffeic acid phenethyl ester reduces the enzyme activity in vivo, suppresses the induction of the enzyme by cisplatin in vivo 11671 3.5.4.4 Caffeine - 882 3.5.4.4 Cd2+ - 52 3.5.4.4 Co2+ - 23 3.5.4.4 coformycin - 2648 3.5.4.4 coformycin a natural product transition state analogue inhibitor 2648 3.5.4.4 coformycin powerful picomolar inhibitor of ADA 2648 3.5.4.4 coformycin complete inhibition of ADA2 at 1 mM 2648 3.5.4.4 cordycepin - 5954 3.5.4.4 corticosterone - 1103 3.5.4.4 corticosterone inhibits the adenosine deaminase activity in an age- and region-specific manner 1103 3.5.4.4 Cu2+ - 19 3.5.4.4 Cu2+ 0.029 mM, 50% inhibition 19 3.5.4.4 Cu2+ 81% inhibition at 5 mM 19 3.5.4.4 D-coformycin powerful picomolar inhibitor of ADA 5440 3.5.4.4 deaza adenosine analogues - 105867 3.5.4.4 Deoxycoformycin - 5147 3.5.4.4 DEPC - 24059 3.5.4.4 diclofenac competitive at 27°C, uncompetitive at 37°C 1291 3.5.4.4 diethyl dicarbonate - 463 3.5.4.4 dodecyltrimethylammonium bromide at low concentrations (approximately 0.1 mM), enzyme activity decreases, it increases at a slightly higher concentration (about 0.2 mM), and finally decreases again (about 0.3 mM), CD spectra of adenosine deaminase and DTAB, determination of helix content, MD calculations 8444 3.5.4.4 EDTA - 21 3.5.4.4 epigallocatechin gallate most abundant and biologically active ?avonoid present in green tea, strong competitive inhibitory activity 1234 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)-3-deazaadenine - 34635 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)-adenine - 11514 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)-adenine 0.1 mM concentration, ADA2 is practically unaffected; 0.1 mM concentration, complete and reversible inhibition 11514 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)-adenine hydrochloride 0.4 nM, 50% inhibition 23131 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)-adenine hydrochloride 0.45 nM, 50% inhibition 23131 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)adenine - 2020 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)adenine i.e. EHNA 2020 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)adenine i.e. EHNA, specific for isozyme ADA1, no inhibition of isozyme ADA2 2020 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)adenine i.e. EHNA, specific for isozyme ADA1 2020 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)adenine i.e. (+)-EHNA 2020 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)adenine EHNA 0.1mM 2020 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)adenine ADA-specific inhibitor, almost complete inhibition at 0.00005 mM 2020 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride i.e. EHNA 69268 3.5.4.4 erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride - 69268 3.5.4.4 ethanol CD spectra of adenosine deaminase and EtOH, determination of helix content, MD calculations 69 3.5.4.4 Fe2+ - 25 3.5.4.4 folic acid - 2840 3.5.4.4 FR234938 i.e. 1-((1R,2S)-2-hydroxy-1-(2-(1-naphthyl)ethyl)propyl)1H-imidazole-4-carboxamine, a non-nucleoside inhibitor, the inhibition is blocked by an A2a adenosine receptor antagonist 69270 3.5.4.4 guanosine - 296 3.5.4.4 heparin - 227 3.5.4.4 Hg2+ - 33 3.5.4.4 Hg2+ 88% inhibition at 5 mM 33 3.5.4.4 HgCl2 inhibition of ADA activity is observed in the soluble fraction at 0.005-0.25 mM HgCl2 (84.6-92.6% respectively), whereas inhibition occurs at 0.005-0.25 mM in membrane fractions (20.9-26% respectively). The inhibition is partially or fully abolished by 0.5 mM dithiothreitol or EDTA 110 3.5.4.4 hypoxanthine - 211 3.5.4.4 IgG anti adenosine deaminase 20955 3.5.4.4 indole-3-acetic acid the plant hormone decreases enzyme activity in hearts, but not in kidney and muscle 2965 3.5.4.4 Inosine - 167 3.5.4.4 Inosine competitive inhibition 167 3.5.4.4 Inosine 31% inhibition at 0.1 mM 167 3.5.4.4 iodoacetamide - 67 3.5.4.4 iodoacetic acid - 213 3.5.4.4 Iodopurine - 93713 3.5.4.4 isosorbide mononitrate significantly decreases adenosine deaminase activity, the half-life of adenosine will be lengthened as a consequence of decreased adenosine deaminase activity 151881 3.5.4.4 K+ - 39 3.5.4.4 kinetin the plant hormone decreases enzyme activity in hearts, but not in kidney and muscle 3475 3.5.4.4 L-cysteine - 74 3.5.4.4 lysozyme - 3115 3.5.4.4 methanol MD calculations, discussion of effects 83 3.5.4.4 methylmercury concentration 0.1, 1.0, 20 M, inhibits adenosine deaminase activity in 7- and 60-day-old rats in a concentration-dependent manner, glutathione (50 microM) and dithiothreitol (50 microM) prevent the reduction of adenosine deaminase activity both in cerebral cortex and hippocampus, garlic alcoholic extract (100 microg/ml) abolishes the reduction of adenosine deaminase 10229 3.5.4.4 metoprolol significantly decreases adenosine deaminase activity, the half-life of adenosine will be lengthened as a consequence of decreased adenosine deaminase activity 151880 3.5.4.4 Mg2+ - 6 3.5.4.4 Mg2+ 0.055 mM, 50% inhibition 6 3.5.4.4 Mg2+ strong inhibition 6 3.5.4.4 Mn2+ - 11 3.5.4.4 Mn2+ 0.046 mM, 50% inhibition 11 3.5.4.4 Mn2+ 85% inhibition at 5 mM 11 3.5.4.4 additional information no inhibition by erythro-9-(2-hydroxy-3-nonyl)-adenine hydrochloride 2 3.5.4.4 additional information structure-based design, synthesis, and structure-activity relationship studies of non-nucleoside adenosine deaminase inhibitors, overview 2 3.5.4.4 additional information molecular dynamic simulations of inhibitor-enzyme interaction, overview 2 3.5.4.4 additional information loss of activity precedes the global secondary and tertiary structure transition when the enzyme is exposed to denaturant, structural mechanism, overview 2 3.5.4.4 additional information no inhibition of the bovine enzyme by 5'-methylthiocoformycin and 5'-methylthio-2'-deoxycoformycin 2 3.5.4.4 additional information no inhibition of the human enzyme by 5'-methylthiocoformycin and 5'-methylthio-2'-deoxycoformycin 2 3.5.4.4 additional information cytotoxic effects of inhibitors against human breast cancer cell lines MCF-7 and MCF-10A 2 3.5.4.4 additional information ADA1 activity is not changed significantly by aspirin, metoprolol, isosorbide mononitrate, and molsidominemolsidomine; molsidomine does not influence plasma adenosine deaminase activity significantly 2 3.5.4.4 additional information the trend of relative activity is directly proportional to helicity and inversely proportional to accessible surface area 2 3.5.4.4 additional information strong inhibition by the traditional Chinese medicines Rhizoma Chuanxiong and Angelica sinensis 2 3.5.4.4 N-ethylmaleimide - 49 3.5.4.4 N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-2-phenylacetamide - 73997 3.5.4.4 N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]-4-(trifluoromethyl)benzamide - 73996 3.5.4.4 N-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]benzamide - 73993 3.5.4.4 N6-methyladenosine - 6566 3.5.4.4 Na+ - 59 3.5.4.4 Na2SO4 CD spectra of adenosine deaminase and Na2SO4, determination of helix content, MD calculations, discussion of effects 733 3.5.4.4 NaCl MD calculations, discussion of effects 42 3.5.4.4 nebularine i.e. 9-beta-D-ribofuranosylpurine, competitive inhibitor 15884 3.5.4.4 NH4+ - 54 3.5.4.4 Ni2+ - 38 3.5.4.4 Ni2+ 61% inhibition at 5 mM 38 3.5.4.4 o-phenanthroline - 239 3.5.4.4 p-chloromercuribenzoate - 43 3.5.4.4 p-chloromercuryphenylsulfonate - 106956 3.5.4.4 p-hydroxymercuribenzoic acid - 4631 3.5.4.4 Pb2+ - 139 3.5.4.4 Pentachlorophenol - 1077 3.5.4.4 pentostatin - 35853 3.5.4.4 pentostatin i.e. (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol 35853 3.5.4.4 pentostatin i.e. 2'-deoxycoformycin, a selective ADA inhibitor 35853 3.5.4.4 phenylhydrazine competitive inhibition 398 3.5.4.4 progesterone progesterone decreases adenosine deaminase levels, adenosine deaminase levels show regional specificity with differences among the cerebral hemispheres, cerebellum, and brainstems structures 286 3.5.4.4 purine competitive inhibition 2218 3.5.4.4 purine riboside - 2984 3.5.4.4 purine riboside adenosine analogue, induces conformational changes inhibiting the enzyme, structural mechanism, overview 2984 3.5.4.4 reduced glutathione - 593 3.5.4.4 simvastatin inhibits ADA1 activity by 46.7%; significantly decreases adenosine deaminase activity, the half-life of adenosine will be lengthened as a consequence of decreased ADA activity 2311 3.5.4.4 Sodium dodecyl sulfate at low concentrations (approximately 0.1 mM) enzyme activity decreases, it increases at a slightly higher concentration (about 0.4 mM), and finally decreases again (about 0.55 mM), CD spectra of adenosine deaminase and SDS, determination of helix content, MD calculations 1358 3.5.4.4 Sodium selenate does not alter enzyme activity 30410 3.5.4.4 spermidine - 148 3.5.4.4 Theobromine - 2761 3.5.4.4 theophylline - 1221 3.5.4.4 thiol reagents - 3246 3.5.4.4 Urea - 116 3.5.4.4 Zn2+ - 14 3.5.4.4 Zn2+ 65% inhibition at 5 mM 14 3.5.4.4 Zn2+ decrease of 31.3% on adenosine deamination in membranes is observed in the presence of 5 mM Zn2+ 14